title: Leveraging chemotherapy-induced lymphopenia to potentiate cancer immunotherapy.
abstract: First-line chemotherapy to combat primary malignant brain cancer is often accompanied by lymphopenic immunologic deficiency. Although counterintuitive, chemotherapy-induced lymphopenia can provide excellent host conditioning that may actually be leveraged to potentiate antitumor immunotherapy. We discuss here our preclinical and clinical experiences applying immunotherapy against glioblastoma, the most common and lethal primary malignant brain tumor, as well as the use of immunotherapeutics in the setting of standard-of-care temozolomide chemotherapy.
authors.affiliation: Duke Brain Tumor Immunotherapy Program; Division of Neurosurgery; Department of Surgery; Duke University Medical Center ; Durham, NC USA ; The Preston Robert Tisch Brain Tumor Center at Duke; Duke University Medical Center ; Durham, NC USA.
authors.forename: Luis
authors.initials: L
authors.lastname: Sanchez-Perez
authors.affiliation: Duke Brain Tumor Immunotherapy Program; Division of Neurosurgery; Department of Surgery; Duke University Medical Center ; Durham, NC USA ; Department of Pathology, Duke University ; Durham, NC USA ; The Preston Robert Tisch Brain Tumor Center at Duke; Duke University Medical Center ; Durham, NC USA.
authors.forename: Carter M
authors.initials: CM
authors.lastname: Suryadevara
authors.affiliation: Department of Neurosurgery; Massachusetts General Hospital and Harvard Medical School ; Boston, MA USA.
authors.forename: Bryan D
authors.initials: BD
authors.lastname: Choi
authors.affiliation: Duke Brain Tumor Immunotherapy Program; Division of Neurosurgery; Department of Surgery; Duke University Medical Center ; Durham, NC USA ; The Preston Robert Tisch Brain Tumor Center at Duke; Duke University Medical Center ; Durham, NC USA.
authors.forename: Elizabeth A
authors.initials: EA
authors.lastname: Reap
authors.affiliation: Duke Brain Tumor Immunotherapy Program; Division of Neurosurgery; Department of Surgery; Duke University Medical Center ; Durham, NC USA ; Department of Pathology, Duke University ; Durham, NC USA ; The Preston Robert Tisch Brain Tumor Center at Duke; Duke University Medical Center ; Durham, NC USA.
authors.forename: John H
authors.initials: JH
authors.lastname: Sampson
keywords: chemotherapy; glioblastoma; immunotherapy; lymphopenia; temozolomide